Plain English Summary
Background and study aims
Congenital heart disease is a general term used to describe a range of birth defects that affect the way the heart works. Children with congenital heart disease often need operations to correct the abnormality that they were born with to improve their chance of survival and quality of life. The surgery is complex and usually involves a period of support on a heart-lung machine (cardiopulmonary bypass) whilst the defect is repaired. The surgery puts a strain on the child’s heart and may potentially cause a type of damage called ischaemia-reperfusion injury (tissue damage when the blood supply to the heart is interrupted and restored). Previous studies have found that using a blood pressure cuff to stop blood flow to one or more limbs (Remote ischemic preconditioning (RIPC)) for short periods immediately before surgery may reduce any damage to the heart during surgery and thereby make the surgery safer. This study is going to look at RIPC in children with two common types of congenital heart conditions, ventricular septal defect (in which there is a hole in the wall between the lower chambers of the heart) and tetralogy of Fallot (a condition which combines four defects in the heart muscle). The aim of this study is to find out whether RIPC improves heart protection in all or just some children.
Who can participate?
Children aged between three months and three years who are undergoing surgery due to a heart defect they were born with (Tetralogy of Fallot or Ventricular Septal Defect).
What does the study involve?
Children are randomly allocated to one of two groups. Those in the first group receive RIPC. This involves placing a tourniquet (precisely controlled blood pressure cuff) around the top of each leg once the child is asleep (under anaesthesia) and inflating it for 5 minutes to stop the blood supply, then deflating it for 5 minutes to allow the blood supply to resume. This is repeated three times to get the most accurate result. For those in the second group, the cuffs are placed beside the patient around a dummy limb for the inflation-deflation cycles. In all cases, the cuffs are covered with a drape to ensure that it is not known which procedure the children receive. For both groups, blood and muscle samples are taken during surgery to measure if there is a difference in how the heart cells make energy between children with normal or low blood oxygen levels and whether this is affected by using RIPC.
What are the possible benefits and risks of participating?
There may not be any benefit from participating as whilst some previous studies have shown that the blood pressure cuff technique helps to protect children’s hearts from injury during surgery, it is unknown whether it is beneficial to all children with all types of congenital heart disease. There are no notable risks of participating, as the technique being used is safe with no complications reported related to the technique in either children or adults undergoing any type of surgery.
Where is the study run from?
Birmingham Children's Hospital (UK)
When is the study starting and how long is it expected to run for?
December 2014 to March 2019
Who is funding the study?
British Heart Foundation (UK)
Who is the main contact?
Mr Nigel Drury
nigel.drury@bch.nhs.uk
Trial website
Contact information
Type
Public
Primary contact
Mr Nigel Drury
ORCID ID
http://orcid.org/0000-0001-9012-6683
Contact details
Department of Cardiac Surgery
Birmingham Children's Hospital
Steelhouse Lane
Birmingham
B4 6NH
United Kingdom
+44 121 333 9435
nigel.drury@bch.nhs.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
1845
Study information
Scientific title
The Birmingham Remote Ischaemic Conditioning in Children trial
Acronym
BRICC
Study hypothesis
1. Remote ischemic preconditioning (RIPC) improves myocardial protection and reduces markers of IR injury in young children undergoing surgery; however, the benefits may be attenuated in those with chronic hypoxia
2. RIPC leads to a reduction in the accumulation of citric acid cycle intermediates during ischaemia; however, this effect may be reduced in those with chronic hypoxia
3. Succinate concentration is significantly higher in the chronically hypoxic myocardium than in the previously normoxic heart, both at the onset and at the end of surgical ischaemia
Ethics approval
Not provided at time of registration
Study design
Single-centre prospective double-blind randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
1. Tetralogy of Fallot
2. Ventricular Septal Defect
Intervention
On the morning of surgery, participants will be randomised to either Remote Ischaemic Preconditioning (RIPC) or control in a 1:1 ratio using an online randomisation system. Patients will be stratified for the congenital heart defect undergoing repair (TOF or VSD) and the presence of a RVOT stent in patients with TOF. In all cases, the cuffs will be covered with a drape to maintain blinding.
RIPC group: After induction of anaesthesia but prior to sternotomy, participants will receive RIPC induced by 3 cycles of 5-minutes ischaemia and 5-minutes reperfusion. Ischaemia will be induced simultaneously in two limbs using the PTSii system (Delfi Medical, Vancouver), a state-of-the-art digital tourniquet with precise control of occlusion pressure. Age-appropriate PediFit cuffs, with Contour limb protection sleeves, will be placed around both thighs and inflated to at least 50mmHg above systolic pressure measured via the arterial line; if vascular access is problematic and the femoral route is required by the anaesthetist, one cuff will be placed on the thigh and the other on the upper arm.
Control group: The cuffs will be placed beside the patient for sham inflation-deflation cycles on a dummy limb.
Following surgery, all patients will be followed-up until discharge from hospital or 30 days, whichever is sooner.
Intervention type
Procedure/Surgery
Phase
Drug names
Primary outcome measures
Myocardial injury, determined by area under the time-concentration curve (AUC) for high-sensitivity troponin-T in the first 24 hours, measured at baseline, 3, 6, 12 and 24 hours after aortic cross-clamp release (reperfusion).
Secondary outcome measures
1. Myocardial injury, measured by peak hs-troponin-T in the first 12 hours, measured at baseline, 3, 6, 12 and 24 hours after reperfusion
2. Myocardial function, measured by cardiac index using the ICON device over the first 12 hours after reperfusion
3. Inotropic support, determined by inotrope score over the first 12 hours after reperfusion
4. Metabolic debt, measured by serum lactate concentration and mixed venous oxygen saturations over the first 12 hours after reperfusion
5. Length of stay, determined by the period of time required in the paediatric intensive care unit and the hospital following surgery
Overall trial start date
11/12/2014
Overall trial end date
31/03/2019
Reason abandoned
Eligibility
Participant inclusion criteria
1. Aged 3 months to 3 years at the time of surgery
2. Undergoing elective primary repair of Tetralogy of Fallot (TOF) or Ventricular Septal Defect (VSD), with or without a concomitant atrial septal defect (ASD)
Participant type
Patient
Age group
Child
Gender
Both
Target number of participants
104
Participant exclusion criteria
1. Those requiring an additional procedure (other than ASD closure) at the time of primary repair e.g. aortic arch repair
2. Those with a known major chromosomal defect, significant airway or parenchymal lung disease, bleeding disorder or recent ischaemic event
3. Those presenting in a critical condition and requiring emergency cardiac surgery
4. Those for whom the parents are unable to give informed consent
Recruitment start date
15/08/2016
Recruitment end date
31/03/2019
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Birmingham Children's Hospital
Steelhouse Lane
Birmingham
B4 6NH
United Kingdom
Sponsor information
Organisation
University of Birmingham
Sponsor details
Edgbaston
Birmingham
B15 2TT
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Charity
Funder name
British Heart Foundation
Alternative name(s)
BHF
Funding Body Type
private sector organisation
Funding Body Subtype
foundation
Location
United Kingdom
Results and Publications
Publication and dissemination plan
The findings of this clinical trial and metabolomics studies will be submitted for presentation at national and international meetings. Manuscripts will be prepared for submission to leading journals.
Intention to publish date
31/12/2019
Participant level data
To be made available at a later date
Results - basic reporting
Publication summary